SCHEMBL6967545

SCHEMBL6967545

CCOC(=O)Cn1cnc2c1CCCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.51
▸ RXFP1 Q9HBX9 2/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ POLB P06746 1/20 0.49
▸ ESR2 Q92731 1/20 0.49
▸ LMNA P02545 4/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ TRPM2 O94759 1/20 0.44
▸ MITF O75030 1/20 0.43
▸ MAPK1 P28482 2/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ RAB9A P51151 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23161482 0.76 PDE3B (0.33) TSHRLMNAALDH1A1RAB9AKDM4E
SCHEMBL4572407 0.72 SMN1; SMN2 (0.46) TSHRPOLBLMNAALDH1A1TRPM2
SCHEMBL16154752 0.72 LMNA (0.48) TSHRPOLBESR2LMNAALDH1A1
SCHEMBL17622533 0.70 KMT2A (0.51) TSHRRXFP1POLBESR2LMNA
SCHEMBL25908800 0.70 POLB (0.46) TSHRRXFP1NPSR1POLBESR2
SCHEMBL15994894 0.70 ALDH1A1 (0.46) TSHRNPSR1POLBESR2LMNA
SCHEMBL9570473 0.69 PDE3B (0.34) HSD17B10
SCHEMBL9597539 0.69 ADORA2A (0.37) LMNARAB9ANPC1HTT
SCHEMBL23510076 0.69 POLB (0.96) TSHRRXFP1POLBESR2LMNA
SCHEMBL7369549 0.69 ALDH1A1 (0.46) TSHRRXFP1POLBESR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610721-B2 Imidazo heterocyclic compounds NOVO NORDISK A/S (DK) 2003-08-26 — — US disclosed
EP-1268483-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 — — EP disclosed
US-20010049385-A1 Imidazo heterocyclic compounds HIGH POINT PHARMACEUTICALS, LLC 2001-12-06 — — US disclosed
WO-2001068651-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049385-A1 Imidazo heterocyclic compounds HRH4, HRH3, HRH2 TSHR 509/4885RXFP1 876/4885NPSR1 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback